This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

PLAC1 in Reproduction

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified December 2014 by Michael Fant, University of South Florida.
Recruitment status was:  Recruiting
March of Dimes
Information provided by (Responsible Party):
Michael Fant, University of South Florida Identifier:
First received: January 13, 2011
Last updated: December 1, 2014
Last verified: December 2014

The PLAC1 gene is a recently described X-linked gene that maps to a region of the X chromosome thought to be important for normal fetal and placental development. Elevated levels of PLAC1 mRNA were detected in preeclampsia and appeared to be directly related to disease severity. PLAC1 may serve as a useful marker of placental dysfunction or threatened pregnancy.

The objective of this study is to measure the prevalence of circulating anti-PLAC1 antibodies in pregnant maternal serum and correlate it with pregnancy outcome. It is likely that women with these antibodies are at higher risk for adverse pregnancy outcomes. Approximately 5% (50 of 1000) will be expected to have anti-PLAC1 antibodies based on previously reported data. The prevalence of these antibodies and their clinical impact on pregnancy outcomes will be determined.

1000 healthy, multiparous and primigravid women will be screened for anti-PLAC1 antibodies at their routine prenatal clinic visits. Subjects will be enrolled at their first clinic visit at USF Health, South Tampa Center, Department of Obstetrics. Blood (1.0 ml) will be obtained as part of the routine blood draw at the time of enrollment. Blood will only be collected when drawn as part of routine laboratory testing as determined by the primary care provider.

Additional blood samples (1.0 ml) will be collected throughout pregnancy at the same time blood is obtained for routine or otherwise clinically indicated laboratory testing. A maximum of 5 samples will be collected through the pregnancy.

Maternal demographic data will be collected and patients will be followed longitudinally to the completion of pregnancy to ascertain their clinical status during pregnancy, onset of premature labor, premature rupture of membranes, delivery date, and gestational age at delivery.


Study Type: Observational
Study Design: Time Perspective: Prospective
Official Title: PLAC1 in Reproduction

Resource links provided by NLM:

Further study details as provided by Michael Fant, University of South Florida:

Primary Outcome Measures:
  • Anti-PLAC1 autoantibodies [ Time Frame: During pregnancy ]

Estimated Enrollment: 1000
Study Start Date: May 2009
Estimated Study Completion Date: May 2015
Estimated Primary Completion Date: May 2015 (Final data collection date for primary outcome measure)

Ages Eligible for Study:   14 Years to 55 Years   (Child, Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
Pregnant women at USF coming in for their first prenatal appointment

Inclusion Criteria:

  • Pregnant, primigravid and multigravid women between the ages of 14 and 55, receiving prenatal care at USF Health, STC, Dept. of Obstetrics.

Exclusion Criteria:

  • presence of significant cardiac disease
  • renal disease
  • chronic hypertension
  • chromosomal abnormalities
  • cancer
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01277848

Contact: Nicole Nations, RN, BSN (813) 259-8848
Contact: Judy Zaritt, RN, BS (813) 259-8746

United States, Florida
USF Health OB/GYN Clinic Recruiting
Tampa, Florida, United States, 33606
Contact: Nicole Nations, RN, BSN    813-259-8848   
Contact: Judy Zaritt, RN, BS    (813) 259-8746   
Principal Investigator: Michael Fant, MD, PhD         
Sub-Investigator: Valerie Whiteman, MD         
Sponsors and Collaborators
University of South Florida
March of Dimes
Principal Investigator: Michael Fant, MD, PhD University of South Florida
  More Information

Responsible Party: Michael Fant, Principal Investigator, University of South Florida Identifier: NCT01277848     History of Changes
Other Study ID Numbers: IRB#107849
Study First Received: January 13, 2011
Last Updated: December 1, 2014

Keywords provided by Michael Fant, University of South Florida:
first prenatal visit
pre-eclampsia processed this record on August 16, 2017